Edgewise Therapeutics (EWTX) PT Raised to $52 at Wedbush

Wedbush analyst Laura Chico raised the price target on Edgewise Therapeutics (NASDAQ: EWTX) to $52.00 (from $46.00) while maintaining a Outperform rating.

The analyst comments "Remain Outperform rated on EWTX, new $52 target. EWTX reached a deal with Servier (not covered) to acquire all rights to sevasemten for $1.55B in upfront cash and an additional $1.1B in milestones. Overall, we see this as a positive deal for EWTX. While we were enthusiastic for sevasemten's potential, advancing both sevasemten and EDG-7500 offered limited synergies for EWTX. The transaction brings in non-dilutive capital to further extend EWTX's runway and allows the company to laser focus on cardiac efforts going forward. Most important near term for EWTX remains the CIRRUS readout in 2Q26 (see preview note) and demonstrating differentiation vs. competitors. From our view, "differentiation" looks like comparable efficacy to what EWTX showed previously and uneventful safety (e.g. no LVEF<50%, AFib in single digits)."

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• RBC Capital on Veeva Systems (VEEV) Amid After Hours Selloff on Earnings: 'we are surprised to see shares trade down'
• Bernstein SocGen Group Starts Cipher Mining (CIFR) at Outperform